KRAS and pancreatic intraductal papillary-mucinous neoplasm: Moreover, 100% and 96% sensitivity and specificity concerning an IPMN were observed during detection regarding KRAS and/or GNAS mutations, whereas 89% and 100% sensitivity and specificity concerning both an IPMN and MCNs (mucinous cystic neoplasms) regarding KRAS and/or GNAS mutations, were noticed during conducting NGS [110, 111].